Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Revenue (2019 - 2025)

Historic Revenue for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $120.7 million.

  • BridgeBio Pharma's Revenue rose 431800.88% to $120.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.8 million, marking a year-over-year increase of 6245.95%. This contributed to the annual value of $221.9 million for FY2024, which is 228527.36% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Revenue stood at $120.7 million, which was up 431800.88% from $110.6 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Revenue ranged from a high of $211.1 million in Q1 2024 and a low of -$830000.0 during Q4 2021
  • Its 5-year average for Revenue is $35.1 million, with a median of $2.3 million in 2021.
  • As far as peak fluctuations go, BridgeBio Pharma's Revenue plummeted by 78032.79% in 2021, and later surged by 1146188.39% in 2024.
  • BridgeBio Pharma's Revenue (Quarter) stood at -$830000.0 in 2021, then soared by 325.3% to $1.9 million in 2022, then dropped by 6.68% to $1.7 million in 2023, then soared by 237.08% to $5.9 million in 2024, then skyrocketed by 1952.02% to $120.7 million in 2025.
  • Its last three reported values are $120.7 million in Q3 2025, $110.6 million for Q2 2025, and $116.6 million during Q1 2025.